Thomas Hawkey, DO
Internal Medicine · Sumter, SCNPI 1043292618
Payments from drug & device makers
Across 292 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$798
- GSK$763
- Boehringer Ingelheim$520
- Kowa Pharmaceuticals America, Inc.$364
- Amarin Pharma, Inc.$323
- Amgen$301
- plus $2K from 26 others
What the payments were for
- Speaking & faculty fees$200%
- Food & beverage$4,997100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 51 | $798 |
| GSK | 43 | $763 |
| Boehringer Ingelheim | 32 | $520 |
| Kowa Pharmaceuticals America, Inc. | 20 | $364 |
| Amarin Pharma, Inc. | 17 | $323 |
| Amgen(2 entities) | 18 | $301 |
| Pfizer | 16 | $298 |
| Lilly USA, LLC | 13 | $236 |
| Bayer | 11 | $172 |
| Esperion Therapeutics, Inc. | 10 | $170 |
| Novartis | 10 | $163 |
| Abbott | 9 | $157 |
| Novo Nordisk | 10 | $154 |
| Astellas Pharma US Inc | 5 | $110 |
| Merck | 5 | $74 |
| AbbVie(2 entities) | 3 | $53 |
| Johnson & Johnson | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Acadia Pharmaceuticals Inc | 1 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Daiichi Sankyo Inc. | 1 | $30 |
| Edwards Lifesciences | 1 | $23 |
| Viatris Specialty LLC | 1 | $22 |
| Vital Connect, Inc | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $20 |
| Shield Therapeutics Inc | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SHINGRIX$115
How this compares
$5,017 in reported general payments places this provider in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 174 | $173,748 |
| FarxigaDapagliflozin Propanediol | 181 | $151,338 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 154 | $148,854 |
| OzempicSemaglutide | 124 | $138,923 |
| JanuviaSitagliptin Phosphate | 95 | $87,636 |
| EliquisApixaban | 80 | $74,259 |
| EntrestoSacubitril/Valsartan | 86 | $71,197 |
| MounjaroTirzepatide | 59 | $61,539 |
| TradjentaLinagliptin | 28 | $35,624 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $27,886 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $24,503 |
| LinzessLinaclotide | 33 | $23,469 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $21,299 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 99 | $21,224 |
| NexletolBempedoic Acid | 40 | $18,610 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Stiolto Respimat | $520 | $237,611231 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $798 | $189,141232 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $763 | $162,413179 claims |
| Novo NordiskOzempic | $154 | $138,923124 claims |
| MerckJanuvia, Janumet Xr | $74 | $102,329115 claims |
| PfizerEliquis | $298 | $74,25980 claims |
| NovartisEntresto | $163 | $71,19786 claims |
| Lilly USA, LLCMounjaro | $236 | $61,53959 claims |
| AbbVieLinzess | $53 | $23,46933 claims |
| Esperion Therapeutics, Inc.Nexletol | $170 | $18,61040 claims |
| BayerKerendia | $172 | $17,15117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Sumter
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
- Jerry BackNorth Charleston$322K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.